Last reviewed · How we verify
NDV-3 vaccine with alum IM
NDV-3 vaccine with alum IM is a Biologic drug developed by NovaDigm Therapeutics, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | NDV-3 vaccine with alum IM |
|---|---|
| Sponsor | NovaDigm Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NDV-3 vaccine with alum IM CI brief — competitive landscape report
- NDV-3 vaccine with alum IM updates RSS · CI watch RSS
- NovaDigm Therapeutics, Inc. portfolio CI
Frequently asked questions about NDV-3 vaccine with alum IM
What is NDV-3 vaccine with alum IM?
NDV-3 vaccine with alum IM is a Biologic drug developed by NovaDigm Therapeutics, Inc..
Who makes NDV-3 vaccine with alum IM?
NDV-3 vaccine with alum IM is developed by NovaDigm Therapeutics, Inc. (see full NovaDigm Therapeutics, Inc. pipeline at /company/novadigm-therapeutics-inc).
What development phase is NDV-3 vaccine with alum IM in?
NDV-3 vaccine with alum IM is in Phase 1.
Related
- Manufacturer: NovaDigm Therapeutics, Inc. — full pipeline